Grants for Schools & Universities

National Institutes of Health · Amount varies

This NIH/NIMH U01 cooperative agreement funds first-in-human and early-stage clinical trials of novel investigational drugs or neuromodulatory devices for psychiatric disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. It emphasizes academia-industry partnerships, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH R33 grant funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is aimed at research organizations rather than individuals. No award amount is specified. The study must follow NIMH's experimental-therapeutics design requirements, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH R01 funds full-scale hybrid effectiveness-implementation clinical trials of mental health treatment, prevention, or services interventions in community and practice settings, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Trials must be well-powered and follow NIMH's experimental-therapeutics approach, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH R01 funds confirmatory efficacy clinical trials of non-pharmacological and pharmacological interventions for mental disorders in adults and children, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Trials must follow NIMH's experimental-therapeutics design, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH award (R61/R33) funds development and testing of novel psychosocial therapeutic and preventive interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Work must follow NIMH's experimental-therapeutics approach, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH award (R61/R33) funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Studies must follow NIMH's experimental-therapeutics design, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIDCD R21 early-career award supports basic and clinical research by scientists beginning an independent research career in NIDCD mission areas such as hearing, balance, smell, taste, voice, speech, or language. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible. It cannot fund thesis or dissertation research, and is intended to generate preliminary data for a later R01. No award amount is specified.

National Institutes of Health · Amount varies

This NIH/NEI R21 funds vision-related research projects based on secondary analysis of existing datasets, including related statistical methodology development; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. The focus is limited to vision-related secondary data analysis.

National Institutes of Health · Amount varies

This NIH/NIDCD U01 cooperative agreement funds clinical trials for the treatment or prevention of communication disorders, specifically trials requiring FDA oversight, intended to establish efficacy, or carrying higher risk. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. Foreign organizations are not eligible. No award amount is specified, and the trial focus makes the scope narrow.

National Institutes of Health · Up to $650K

This NIH limited-competition award (UG3/UH3) funds collaborative innovation projects within the CTSA Program consortium to accelerate translational research. Eligibility is restricted per the funding notice, and foreign organizations and their U.S. components are not eligible, so this is aimed at institutions already in or aligned with the CTSA consortium rather than the general public. Awards run up to roughly $650,000. Review the notice's eligibility section closely, as access is limited.

National Institutes of Health · $50K–$300K

This NIH/NCI U01 funds early-stage development of informatics tools and technologies that improve how cancer research data is acquired, managed, analyzed, and shared. Eligibility is described in the funding notice, and foreign organizations and their U.S. components may apply. Awards run from about $50,000 up to $300,000. Projects must engage end users and show clear potential to advance cancer research, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NINDS award (R61/R33) funds pharmacology and in vivo efficacy studies to advance candidate therapeutics for neurological and neuromuscular disorders toward further translational development. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations rather than individuals. No award amount is specified. The work is narrowly defined preclinical drug-development research.

National Institutes of Health · Up to $750K

This NIH/NINDS award (R61/R33) funds development of in vitro and ex vivo assays and screening to identify candidate therapeutics for neurological and neuromuscular disorders; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The early-stage drug-discovery focus makes the scope narrow.

National Institutes of Health · Up to $750K

This NIH/NINDS award (R61/R33) funds development and validation of animal models and tissue systems that mimic neurological and neuromuscular disorders to support future neurotherapeutic discovery; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The model-development focus makes the scope narrow.

National Institutes of Health · Amount varies

This NIH/NCI R34 planning grant funds the design and preparation of cancer prevention and control clinical trials, covering screening, early detection, supportive care, and survivorship. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations, not individuals. No award amount is specified. It funds trial-planning activities rather than the trials themselves.

National Institutes of Health · Amount varies

This NIH/NCI U34 planning grant funds the design and preparation of cancer prevention and control clinical trials, including studies on screening, early detection, and survivorship. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it is aimed at research organizations, not individuals. No award amount is specified. It funds trial-planning work rather than the trials themselves, so review the scope carefully.

National Institutes of Health · Amount varies

This NIH/NIMH U01 funds individual research projects to discover and develop new drugs and neurostimulation approaches for mental disorders, substance use disorders, and alcohol use disorder. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. The drug/device discovery focus makes the scope narrow.

National Institutes of Health · Amount varies

This NIH/NIMH U19 funds multi-project programs to discover and develop new drugs and neurostimulation approaches for mental disorders, substance use disorders, and alcohol use disorder. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations, not individuals. No award amount is specified. It supports large multidisciplinary programs, so the scope is narrow.

National Institutes of Health · Up to $375K

This NIH R15 (REAP) award funds small-scale research and student research experiences at health-professional and graduate schools that receive limited NIH funding, with a minimal-risk clinical trial required. Eligibility is restricted to degree-granting institutions that have received no more than $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. Awards reach up to about $375,000. The NIH-funding cap and institution-type limits make eligibility narrow, so verify your institution qualifies.

National Institutes of Health · Amount varies

This NIH/NINDS U01 is a limited competition open only to applicants holding existing NINDS-supported clinical trial cooperative agreement awards that need more time and resources to finish. Because it is restricted to current grantees, new applicants are not eligible; foreign organizations are also excluded. No award amount is specified. This opportunity does not apply to organizations that do not already hold the relevant NINDS award.